ments are taken into account in the decision about the treatment of selected MS patients, then immunosuppression is thoroughly justified. The restrictions I have given imply, nevertheless, that at the present time one cannot advocate the general application of immunosuppression as a standard form of MS treatment. However, in the framework of strictly controlled and monitored clinical trials the effects of immunosuppression in MS patients should be studied further, and this may not only be of some benefit for, I hope, an increasing number of patients, but may eventually also add to our knowledge about the pathological processes underlying this disease. REFERENCES Arnon R (1975) For forty years cavalry brigades of research workers have attacked the fortress of multiple sclerosis (MS), spurred on by its alleged similarity with experimental allergic encephalomyelitis (EAE). The histological brigade report that EAE in large primates and human post-rabies vaccine encephalomyelitis resemble the active lesions of multiple sclerosis. The experimental pathologists have kept the battle going with descriptions of chronic, even relapsing, forms of EAE in the guinea-pig (Snyder et al. 1975 ). The brigade of immunologists have successfully demonstrated that EAE is caused by a T-cell mediated immune response against myelin basic protein (molecular weight 18 000). Antibody to myelin basic protein is produced but is not necessary for disease production. Antibodies to other myelin antigens are also produced but do not induce disease, and may even have a protective effect (Hughes 1974 , Hughes & Leibowitz 1975 . The onus is now on the immunological cavalry to identify similar phenomena in MS.
The most easily detectable marker of any immune response to basic protein would be antibody. Attempts to find such antibody by radioimmunoassay in the serum of MS patients have been uniformly unsuccessful (Lisak et al. 1968 , Lennon & Mackay 1972 , Schmid et al. 1974 ). The cerebrospinal fluid (CSF) of MS patients contains oligoclonal bands of IgG which are not present in the serum, but antibody to basic protein has not been found in these bands. Possibly the excess basic protein present in the CSF of patients with active MS (Cohen et al. 1976 ) might mask the presence of antibodies.
A multitude of different techniques have been used to detect cell-mediated immunity to basic protein, with conflicting results (Hughes & Leibowitz 1977) . The most suggestive work is that of Sheremata et al. (1976) who claim that cellmediated immunity to basic protein is indeed present at the time of or shortly before a relapse of Section ofNeurology multiple sclerosis and disappears during remissions. Their assay system depended on the inhibition of guinea-pig macrophage migration by the patient's lymphocytes. The test is by no means specific for multiple sclerosis and positive results are also obtained in patients with stroke.
We have recently re-explored this problem using a microculture technique for the estimation of lymphocyte transformation in the presence of human myelin basic protein. Lymphocytes were separated from venous blood on a Ficoll-triosil gradient. After washing, 200 pl of a cell suspension containing 2 x 105 cells in bicarbonate buffered tissue culture medium with 100% AB serum were placed in each well of a flat-bottomed microtiter tray. The wells were labelled with 0.166 pCi of 3-H thymidine after 5 days and harvested after 6 days. The control uptake of 3-H thymidine in unstimulated cultures was greater in patients with MS and other neurological diseases (OND) than in normal subjects (Fig 1) . Responses to antigens or mitogens were expressed as the increment of uptake above the unstimulated cultures. Responses to phytohxmagglutinin (PHA) and purified protein derivative (PPD) were similar in all three groups, except that the response to PHA was somewhat lower in those with other neurological (Fig 2) . Myelin basic protein produced significant transformation in many patients in all three groups. The peak response was at 100-500 gg/ml with rather less transformation at 1000 jsg/ml. There was no significant difference in the responses between the groups at any concentration of antigen (Fig 3) , except that at 10 ,ug/ml there was slightly more transformation in the MS group than in those with other neurological diseases. The results were re-analysed to look for differences in subgroups of MS patients according to clinical activity of disease, disability status, and duration of disease. The only significant result to emerge (Fig 4) was that those who had had MS for longer had greater responses than the normal group at 100 and 500,g/ml (P <0.05 two tailed Student's t test). These results suggest that lymphocyte transformation in the presence of myelin basic protein is a non-specific response, occurring in normal people as well as in many neurological disorders. It might represent a true autoimmune reaction to basic protein released from damaged myelin or a cross-reaction with bacterial, viral or other antigens encountered in everyday life. In the later stages of multiple sclerosis progressive deterioration is not uncommon and clear relapses and remissions cannot be discerned. The immunological events in this late stage may differ from those in the earlier acute relapse, and immune responses to myelin antigens might be more important.
